Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Forte Biosciences, Inc. 宣佈獲得領先醫療機構投資者超額認購的5300萬美元定向增發，以推動FB102在自身免疫相關適應症中的發展。
